C4 Therapeutics Inc (CCCC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at C4 Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 15 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.50 $ — 60% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 280.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.96 | -1.06 – -0.83 | 19 | 15.9% | 5 |
| 12/31/2027 | -1.04 | -1.15 – -0.93 | 19 | -8.8% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.23 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.31 | – | 5 | 58.80 | -667.80 | -18 | -18 |
| 2025: Q1 | -0.24 | – | 7 | 138.20 | -363.70 | -33 | -33 |
| 2025: Q2 | -0.24 | – | 7 | -46.20 | -402.60 | -12 | -12 |
| 2025: Q3 | -0.29 | – | 11 | -26.90 | -286.40 | -31 | -32 |
| 2025: Q4 | -0.19 | – | 11 | 112.80 | -186.00 | -22 | -22 |
| 2026: Q1 | -0.23 | – | 6 | -15.00 | -408.50 | -30 | -30 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 19 | -16 | -16 | -0.37 | -17 | -80 | 146 |
| 2019 | 21 | -35 | -34 | -0.79 | 56 | -112 | 118 |
| 2020 | 33 | -60 | -66 | -1.54 | -67 | 281 | 400 |
| 2021 | 46 | -82 | -84 | -1.82 | -87 | 390 | 507 |
| 2022 | 31 | -130 | -128 | -2.62 | -106 | 289 | 431 |
| 2023 | 21 | -139 | -132 | -2.67 | -107 | 246 | 376 |
| 2024 | 36 | -120 | -105 | -1.52 | -65 | 216 | 350 |
| 2025 | 36 | -104 | -105 | -1.27 | -99 | 257 | 359 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
C4 Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt neuartige Therapiekandidaten zum Abbau krankheitsverursachender Proteine.
| Employees | 104 |
|---|---|
| Headquarters | Watertown, MA |
| Address | 490 Arsenal Way, 02472 Watertown, United States |
| Phone | 617 231 0700 |
| Website | c4therapeutics.com |
| IPO Date | 2. Oct 2020 |
| ISIN | US12529R1077 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Andrew J. Hirsch M.B.A. | CEO, President & Director | 1971 |
| Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 1951 |
| Kendra R. Adams | Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | 1977 |
| Leonard M. J. Reyno M.D. | Chief Medical Officer | 1962 |
| Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Reyno Leonard | Chief Medical Officer | Other | 7,397 | 4.06 | 30,032 |
| 10. Jul 2026 | Reyno Leonard | Chief Medical Officer | Other | 15,325 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.